Related Experiment Video
Updated: Jun 17, 2026
12:22
A Strategy to Identify Compounds that Affect Cell Growth and Survival in Cultured Mammalian Cells at Low-to-Moderate Throughput
Published on: September 22, 2019
Summary
Early clinical data show that KRASG12D-selective inhibitors may be effective treatments for solid tumors. These drugs, including RNK08594, GFH375, and DN022150, show promise for pancreatic cancer and lung cancer.
Area of Science:
- Oncology
- Molecular Biology
- Clinical Pharmacology
Background:
- KRAS mutations are common drivers in many solid tumors.
- Targeting KRASG12D offers a specific therapeutic strategy.
- Development of selective inhibitors is crucial for effective treatment.
Purpose of the Study:
- To present early clinical data for novel KRASG12D-selective inhibitors.
- To evaluate the potential role of these inhibitors in treating solid tumors.
- To highlight promising therapeutic candidates for KRAS-mutated cancers.
Main Methods:
- Early-phase clinical trials evaluating KRASG12D-selective inhibitors.
- Assessment of clinical activity and safety profiles.
- Analysis of patient populations with specific KRAS mutations.
Main Results:
- Encouraging early clinical data were presented for RNK08594, GFH375, and DN022150.
- These KRASG12D-selective inhibitors demonstrated potential efficacy.
- Promising activity observed in pancreatic ductal adenocarcinoma and non-small cell lung cancer.
Conclusions:
- KRASG12D-selective inhibitors represent a promising new class of drugs.
- These agents may play a significant role in treating KRASG12D-mutated solid tumors.
- Further clinical development is warranted to confirm efficacy and safety.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...